Department of Health and Human Services$1.1M obligationsEnds Dec 18, 2021
Federal contract award
HHSN272201500032C
IGF::OT::IGF DUAL AFFINITY RE-TARGETING MOLECULES FOR HIV-1 SUPPRESSION
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541712 |
| PSC | AN81 — AIDS RESEARCH - BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $25.1M |
| Current contract value | $25.1M |
| Potential contract value / ceiling | $25.1M |
| Start date | Sep 14, 2015 |
| Current end date | Jul 14, 2023 |
| Potential end date | Jul 14, 2023 |
| Latest award activity | Sep 9, 2022 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 16 of 16 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 10, 2026 | P00015 | $-549.7K | TO ADMINISTRATE DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2021 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2026, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS. |
| Sep 5, 2024 | P00014 | $0 | DUAL AFFINITY RE-TARGETING MOLECULES FOR HIV-1 SUPPRESSION |
| Jul 3, 2023 | P00013 | $0 | DUAL AFFINITY RE-TARGETING MOLECULES FOR HIV-1 SUPPRESSION |
| Sep 9, 2022 | P00012 | $0 | DUAL AFFINITY RE-TARGETING MOLECULES FOR HIV-1 SUPPRESSION |
| Jun 7, 2022 | P00011 | $0 | DUAL AFFINITY RE-TARGETING MOLECULES FOR HIV-1 SUPPRESSION |
| Feb 23, 2022 | P00010 | $0 | DUAL AFFINITY RE-TARGETING MOLECULES FOR HIV-1 SUPPRESSION |
| Nov 5, 2021 | P00009 | $0 | EO14042 - DUAL AFFINITY RE-TARGETING MOLECULES FOR HIV-1 SUPPRESSION |
| Jul 13, 2021 | P00008 | $6.3M | THE OBJECTIVES OF THIS CONTRACT ARE TO PERFORM PRODUCT DEVELOPMENT AND ADVANCE THERAPEUTIC PRODUCTS, DUAL AFFINITY RE-TARGETING (DART)-1 AND DART-2, INTO PHASE 1/2 CLINICAL TRIALS FOR USE AS THERAPEUTIC AGENTS, IN COMBINATION WITH LATENCY REVERSING T |
| Dec 23, 2020 | P00007 | $0 | THE OBJECTIVES OF THIS CONTRACT ARE TO PERFORM PRODUCT DEVELOPMENT AND ADVANCE THERAPEUTIC PRODUCTS, DUAL AFFINITY RE-TARGETING (DART)-1 AND DART-2, INTO PHASE 1/2 CLINICAL TRIALS FOR USE AS THERAPEUTIC AGENTS, IN COMBINATION WITH LATENCY REVERSING T |
| Apr 13, 2020 | P00006 | $-671.4K | THE OBJECTIVES OF THIS CONTRACT ARE TO PERFORM PRODUCT DEVELOPMENT AND ADVANCE THERAPEUTIC PRODUCTS, DUAL AFFINITY RE-TARGETING (DART)-1 AND DART-2, INTO PHASE 1/2 CLINICAL TRIALS FOR USE AS THERAPEUTIC AGENTS, IN COMBINATION WITH LATENCY REVERSING T |
| Sep 19, 2019 | P00005 | $0 | THE OBJECTIVES OF THIS CONTRACT ARE TO PERFORM PRODUCT DEVELOPMENT AND ADVANCE THERAPEUTIC PRODUCTS, DUAL AFFINITY RE-TARGETING (DART)-1 AND DART-2, INTO PHASE 1/2 CLINICAL TRIALS FOR USE AS THERAPEUTIC AGENTS, IN COMBINATION WITH LATENCY REVERSING T |
| Aug 13, 2019 | P00004 | $0 | THE OBJECTIVES OF THIS CONTRACT ARE TO PERFORM PRODUCT DEVELOPMENT AND ADVANCE THERAPEUTIC PRODUCTS, DUAL AFFINITY RE-TARGETING (DART)-1 AND DART-2, INTO PHASE 1/2 CLINICAL TRIALS FOR USE AS THERAPEUTIC AGENTS, IN COMBINATION WITH LATENCY REVERSING T |
| Jun 28, 2018 | 3 | $1.3M | THE OBJECTIVES OF THIS CONTRACT ARE TO PERFORM PRODUCT DEVELOPMENT AND ADVANCE THERAPEUTIC PRODUCTS, DUAL AFFINITY RE-TARGETING (DART)-1 AND DART-2, INTO PHASE 1/2 CLINICAL TRIALS FOR USE AS THERAPEUTIC AGENTS, IN COMBINATION WITH LATENCY REVERSING TREATMENTS, AND TO DEPLETE HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION THAT PERSISTS DESPITE THE PRESENCE OF EXISTING COMBINATION ANTI-RETROVIRAL THERAPY. |
| Aug 30, 2017 | 2 | $10.8M | IGF::OT::IGF DUAL AFFINITY RE-TARGETING MOLECULES FOR HIV-1 SUPPRESSION |
| Jun 14, 2017 | 1 | $0 | IGF::OT::IGF DUAL AFFINITY RE-TARGETING MOLECULES FOR HIV-1 SUPPRESSION |
| Sep 14, 2015 | 0 | $7.4M | IGF::OT::IGF DUAL AFFINITY RE-TARGETING MOLECULES FOR HIV-1 SUPPRESSION |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.